title: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.
abstract: BACKGROUND
  Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm. The present study assessed survival, value of World Health Organisation (WHO) classification and prognostic utility of clinicopathological parameters at diagnosis.
  
  
  METHODS
  From 1990 to 2004, 180 patients with NF-PETs were entered in a prospective database, and predictors of prognosis were tested in uni- and multivariate models.
  
  
  RESULTS
  There were 25 (14%) benign lesions, 38 (21%) neoplasms of uncertain behaviour, 100 well-differentiated carcinomas (56%) and 17 poorly differentiated carcinomas (9%). Radical resection was possible in 93 cases (51.6%). Overall 5-, 10- and 15-year survival rates were 67%, 49.3% and 32.8%, respectively, and were significantly higher in radically resected patients (93%, 80.8% and 65.2%, respectively; P < 0.00001). By multivariate analysis, poor differentiation [hazard ratio (HR) 7.3; P = 0.0001], nodal metastases (HR 3.05; P = 0.02), liver metastases (HR 3.29; P = 0.003), K(i)-67 >5% (HR 2.5; P = 0.012) and weight loss (HR 3.06; P = 0.001) were significantly associated with mortality.
  
  
  CONCLUSIONS
  This study confirms the good long-term survival of patients with NF-PETs and the prognostic value of WHO classification, liver metastases, poor differentiation, Ki-67, nodal metastases and weight loss. These latter two parameters have a prognostic value similar to that of liver metastases and Ki-67.
authors.affiliation: Department of Surgical and Gastroenterological Sciences, University of Verona, Verona, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Bettini
authors.forename: L
authors.initials: L
authors.lastname: Boninsegna
authors.forename: W
authors.initials: W
authors.lastname: Mantovani
authors.forename: P
authors.initials: P
authors.lastname: Capelli
authors.forename: C
authors.initials: C
authors.lastname: Bassi
authors.forename: P
authors.initials: P
authors.lastname: Pederzoli
authors.forename: G F
authors.initials: GF
authors.lastname: Delle Fave
authors.forename: F
authors.initials: F
authors.lastname: Panzuto
authors.forename: A
authors.initials: A
authors.lastname: Scarpa
authors.forename: M
authors.initials: M
authors.lastname: Falconi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D002277:Carcinoma / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000032:analysis; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010180:Pancreatectomy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D015431:Weight Loss
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen